ImmunoBiome is developing microbiome therapeutics to treat incurable diseases like cancer and autoimmune diseases. Their products include Avatiome™, a pre-clinical model system, and live biotherapeutic candidates IMB001 and IMB002.

Vision and Mission: ImmunoBiome aims to harness the power of the immune system to improve health for all, envisioning a future where life expectancy and access to lifesaving care are not dependent on location or socioeconomic status.

Noteworthy Points:

• ImmunoBiome has raised $27.2M in funding.
• They have 8 investors including KOREA INVESTMENT & SECURITIES and KTB Network.
• The company is located in Pohang, Kyongsang-bukto, South Korea.